Novel immunotherapy 5F9 plus rituximab well tolerated with rapid and durable responses in RR DLBCL and indolent lymphoma

Novel immunotherapy 5F9 plus rituximab well tolerated with rapid and durable responses in R/R DLBCL and indolent lymphoma

06:59 EDT 15 Jun 2019 | ecancermedicalscience

Dr Mark Roschewski presents results at the 2019 European Hematology Association (EHA) Annual Meeting from a study looking at the novel immunotherapy 5F9 plus rituximab which blocks CD47, a key macrophage/cancer checkpoint. The 100 patients studied with...

More From BioPortfolio on "Novel immunotherapy 5F9 plus rituximab well tolerated with rapid and durable responses in R/R DLBCL and indolent lymphoma"